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Background:  Fibrin  sealant  is frequently  used  in knee  surgery  as  an  adjuvant  method  for  reducing  post-
operative  bleeding,  however,  there  is  no consensus  regarding  the  efﬁcacy  of ﬁbrin  sealant.
Hypothesis:  Fibrin  sealant  achieves  better  efﬁcacy  in  terms  of blood  loss  control,  transfusion  rate  and
units  in  knee surgery  compared  with  controls.
Methods: A search  of  the  Cochrane  Collaboration  (2013  Issue  09),  Embase  (1974–2013.09),  PubMed
(1966–2013.09)  and  Chinese  databases  (up  to  2013.09)  were  conducted.  The Cochrane  Collaboration’s
tool  was used  to assess  for  bias  and  data  were  analyzed  by  RevMan  5.29  software.
Results: This  study  included  nine  RCTs and  four  prospective  comparative  trials  with  a total  of  1299
patients.  Compared  to  the  control,  ﬁbrin  sealant  achieved  a decrease  in hemoglobin  reduction  [MD = 1.14,
95%  CI (0.61–1.67)],  transfusion  rate  [OR =  0.36,  95% CI (0.25–0.51)],  transfusion  units  [MD  =  0.47,  95%  CI
(0.24–0.71)],  hospital  stay  [MD  = 2.22,  95%  CI (0.56–3.88)]  and  the  incidence  of  complications  [OR  =  0.56,
95%  CI (0.38–0.83)].  And  it  also  reduced  total  blood  loss,  while  there  was  no  signiﬁcant  difference
[MD  =  155.83,  95%  CI  (–525.02–213.15)].
Conclusion:  Patients  undergoing  knee  surgery  would  beneﬁt  from  high-dose  ﬁbrin  sealant  with  reduced
transfusion  rate  and unit,  hospital  stay  and  complications,  while  they  might  beneﬁt little  from  it  in  total
blood  loss.  However,  the  effects  of a low-dose  of  ﬁbrin  in  knee  surgery  remain  inconclusive.
Level  of evidence:  Level  III.
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.. Introduction
Serious knee arthritis can lead to varying degrees of pain and/or
unctional disability, including decreased ﬂexion and extension
bility [1]. Total knee arthroplasty (TKA) and total knee replace-
ent (TKR) are both common, successful surgeries that are widely
sed to treat patients with serious knee arthritis [2]. TKA and TKR
re frequently followed by postoperative bleeding and often result
n signiﬁcant blood loss. The drain output from patients, measured
sing knee drains, ranges from 1200 mL  to 1800 mL  [2,3], though
his can be even higher due to hidden blood loss [4,5]. A tourniquet
s always used intra-operation, but a meta-analysis by Tai et al.
howed that this could only save operation time [6], not reduce
lood loss [7]. In addition, patients managed with a tourniquet can
ave higher risks of thromboembolic complications postoperation
8].
∗ Corresponding author. Tel.: +86 931 894 2227.
E-mail address: Yangtongqun609@163.com (T.Q. Yang).
http://dx.doi.org/10.1016/j.otsr.2014.07.035
877-0568/© 2014 Elsevier Masson SAS. All rights reserved.Fibrin sealant is comprised mostly of ﬁbrinogen and human
thrombin [9] and can initiate the last phase of physiological blood
coagulation [10]. Although it has been used for decreasing postop-
erative blood loss in surgery for 20 years, the effects of ﬁbrin sealant
on knee surgery remain unclear. Some studies have indicated
that additional ﬁbrin sealant signiﬁcantly reduces blood loss, thus,
reducing the need for blood transfusion [2,11,12]. Other studies
have shown that the difference in blood transfusion requirement
between ﬁbrin sealant groups and control groups were not statis-
tically signiﬁcant [13,14]. Furthermore, the cost of the additional
ﬁbrin sealant is three times greater than that of the required blood
transfusion [2].
To date, there is no consensus in the medical community
with regard to the efﬁcacy of ﬁbrin sealant in knee surgery
and there is limited evidence from systematic reviews or meta-
analyses. In this study, we  evaluate the efﬁcacy and safety of
ﬁbrin sealant in knee surgery through analysis of relevant ran-
domized controlled trials (RCTs) and prospective comparative
studies. The hypothesis of the present study was that ﬁbrin
sealant achieves better efﬁcacy in knee surgery compared with
controls. The use of ﬁbrin sealant allows decreasing the total
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lood loss, the transfusion rate and the mean transfusion unit in
KR.
. Materials and methods
.1. Literature search
Online databases, such as the Cochrane Library (2013 Issue 09),
mbase (1974–2013.09), PubMed (1966–2013.09) and the Science
itation Index Expanded were searched up to September 2013. In
ddition, our search included the following Chinese databases: the
hinese biomedicine literature database (CMB), the Chinese peri-
dical full text database (CNKI) and the Wan  fang database, and they
ere all searched up to September 2013. A range of search terms
ere used: “(knee surgery OR total knee arthroplasty OR TKA OR
otal knee replacement OR TKR) AND (ﬁbrin sealant OR ﬁbrin glue
R ﬁbrin tissue adhesive)”. Based on the primary search results,
uture supplementary searches included reading abstracts, studies,
onference proceedings and citations.
.2. Inclusion criteria
Only published RCTs and prospective comparative studies
ere included, regardless of blinding and allocation concealment.
eviews, case reports and experience-based communications were
xcluded from the study. Patients suffering from serious bilateral or
nilateral knee joint disease who were willing to receive total knee
rthroplasty or total knee replacement were eligible for inclusion in
he study. Participants were divided into two groups: the treatment
roup was treated with ﬁbrin sealant during surgery and the control
roup was not. Other interventions, including drugs and functional
ecovery training, were permitted only when comparable between
he two groups.
The main outcome measures were total blood loss, transfusion
ate, and transfusion units. Secondary outcome measures were Hb
eduction, drain-out volume, hospital stay, and complications.
.3. Data extraction and quality assessment
All studies obtained from the initial searches were indepen-
ently assessed for eligibility by two researchers according to
peciﬁc characteristics. Only studies evaluating the effectiveness
f ﬁbrin sealant in TKA or TKR were considered and analyzed.
ext, two researchers independently extracted the data for the
utcome measures. Three reviewers independently performed a
ethodological quality assessment on the studies according to
he Cochrane Handbook [15], based on methods of randomization,
llocation concealment, blinding, comparable baseline, follow-up,
nd free of selective reporting. Any disagreements about eligibility,
ethodological quality and data were resolved through discussion.
.4. Statistical analysis
Statistical analysis was  performed using RevMan 5.29. Hetero-
eneity was estimated using the Chi2 test and was  considered to
e signiﬁcant when I2 > 50%; in this case, a random-effects model
as applied. When there was not signiﬁcant heterogeneity, a ﬁxed-
ffects model was  applied. Effect size was expressed using a relative
dds ratio (OR) for dichotomous data and mean differences (MD)
or continuous data and all 95% conﬁdence intervals (95% CI) were
resented. Subgroup meta-analysis, including low-dose (≤ 5 mL)
nd high-dose (> 5 mL)  [9] was conducted. Sensitivity analysis and
ublication bias were also performed. Surgery & Research 101 (2015) 331–339
3. Results
3.1. Flow diagram of trial selection
Nine RCTs [11–14,16,17,20–22] and four prospective compar-
ative studies [2,13,18,23] assessing the use of ﬁbrin sealant in
patients who received knee surgery were retrieved from electronic
databases. Of these, two  studies reported data from one trial and
both of them were included [13,23]. Another study contained three
arms: two ﬁbrin sealant arms (5 mL  and 10 mL,  respectively) and
one control arm; we  deemed this two independent trials [17]. The
ﬂow diagram (Fig. 1) illustrates the trial selection process from the
results of the initial literature search to the ﬁnal decision.
3.2. Characteristics and methodological quality of included
studies
Table 1 shows speciﬁc characteristics including sample size, age,
preoperative Hb level, and intervention. A total of 1299 patients
were included in the study. The methodological quality of each
study was assessed using the Cochrane handbook 5.0.1 and the
results are shown in Table 2.
3.3. Effect size of interventions
3.3.1. Blood loss
Both drain-out blood loss and total blood loss were reported.
A total of seven studies [11,14,16–18,20,22] reported data on
drain-out blood loss and there was heterogeneity between them
(I2 = 94%). The random-effects model revealed that ﬁbrin sealant
signiﬁcantly reduced drain-out blood loss by a mean of 316.81 mL
compared to the control group [95% CI (180.76–452.87); P < 0.01]. A
subgroup analysis of four studies [2,16,19,20] reported total blood
loss and random-effects model showed that ﬁbrin sealant reduced
the total blood loss by a mean of 155.93 mL,  but it failed to reach sta-
tistical signiﬁcance [95% CI (–525.02–213.15); I2 = 86%], as shown
in Fig. 2.
To further explore the dose-effect, we also performed another
subgroup analysis. A subgroup analysis of two  studies [11,17]
showed that a low-dose of ﬁbrin sealant reduced drain-out put by
a mean of 391.28 mL  [95% CI (313.10–469.47); P = 0.60; I2 = 0%]. A
subgroup analysis of four studies [14,17,18,22] revealed that a high-
dose of ﬁbrin sealant obtained a reduction in blood loss by a mean
of 319.09 mL  [95% CI (93.2–544.98); P = 0.006; I2 = 96%], as shown
in Fig. 3.
3.3.2. Transfusion rate
Eight studies [2,11–14,17,19,20] were analyzed for transfusion
rate. The ﬁxed-effects model revealed that ﬁbrin sealant reduced
transfusion rate compared to control group [OR = 0.36; 95% CI
(0.25–0.51); I2 = 0%]. A subgroup analysis of three studies [2,11,17]
showed that a low-dose of ﬁbrin sealant reduced transfusion rate
[OR = 0.27; 95% CI (0.14–0.50); I2 = 0%]. Finally, a subgroup analy-
sis of seven studies [2,12–14,17,19,20] showed that a high-dose
of ﬁbrin sealant reduced transfusion rate compared to the control
group [OR = 0.40; 95% CI (0.27–0.62); I2 = 42%], as shown in Fig. 4.
3.3.3. Blood transfusion unit
Due to signiﬁcant heterogeneity (I2 = 78%), the random-effects
model was applied and this revealed that ﬁbrin sealant reduced
blood transfusion units by a mean of 0.47 U compared to the con-
trol group [95% CI (0.24–0.71); P < 0.0001]. A subgroup analysis of
two studies [2,17] showed that a low-dose of ﬁbrin sealant reduced
blood transfusion units by a mean of 0.45 U [95% CI (0.17–0.73);
P = 0.73; I2 = 0%]. A subgroup analysis of ﬁve studies [11,13,17–19]
showed that high-doses of ﬁbrin sealant reduced blood transfusion
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Fig. 1. Flow diagram shows literature process from initial search to ﬁnal selection result.
Table 1
Characteristics of trials included in this meta-analysis.
Study Year Study
design
Case
(T/C, n)
Age (T/C, y) Pre-operative Hb
(T/C, g/dL)
Intervention
Massin et al. [2] 2012 pCS 31/31 69 ± 10/72 ± 8 14.0 ± 1.0/13.0 ± 1.2 5 mL  FS vs blank control
Kluba  et al. [21] 2012 pRCT 12/12 70.8 ± 5.6/71.0 ± 10.6 – 2 mL  FS vs blank control
Sabatini et al. [11] 2012 pRCT 35/35 70.7 ± 6.4/70.4 ± 6.7 13.2 ± 1.3/13.5 ± 1.5 5 mL  FS vs postoperative blood
recovery and reinfusion
Notarnicola et al. [17] 2012 pRCT 30/30 69.2 ± 8.2 13.4 ± 1.2/13.7 ± 1.1 5 mL  FS vs blank control
30/30  13.0 ± 1.0/13.7 ± 1.1 10 mL  FS vs blank control
Levy  et al. [16] 1999 pRCT 29/29 68.9 ± 6.3/70.2 ± 8.2 – 5–10 mL FS vs blank control
Skovgaard et al. [22] 2012 pRCT 24/24 33–81 – 10 mL  FS vs saline
Wang  et al. [14] 2001 pRCT 25/28 – 13.5 ± 0.3/13.2 ± 0.3 10 mL  FS vs blank control
Wang  et al. [12] 2003 pRCT 107/97 68.2 ± 8.3/68.9 ± 8.7 3.0 ± 0.2/3.5 ± 0.2 10 mL  FS vs blank control
Everts  et al. [13] 2006 pCS 85/80 69.4 ± 9.1/67.4 ± 9.9 13.6 ± 1.1/13.7 ± 1.1 9 mL  FS vs blank control
Everts  et al. [23] 2007 pCS 85/80 69.4 ± 9.1/67.4 ± 9.9 13.6 ± 1.1/13.7 ± 1.1 9 mL  FS vs blank control
Spinarelli et al. [18] 2011 pCS 64/46 – – 10 mL  FS vs blank control
.6 ± 1.
T ized co
u
a
3
r
T
Q
N
UMolloy  et al. [19] 2006 pRCT 50/50 – 
Aguilera et al. [20] 2001 pRCT 43/43 72
: treatment group; C: control group; FS: ﬁbrin sealant; pRCT: prospective random
nits by a mean of 0.48 U [95% CI (0.18–0.78); P = 0.002; I2 = 85%],
s shown in Fig. 5..3.4. Hemoglobin (Hb) reduction
Six studies reported Hb reduction [11,14,16–18] and the results
evealed that ﬁbrin sealant led to a signiﬁcant decrease in Hb
able 2
uality assessment of the included trials.
Study Randomization Allocation
concealment
Blinding 
Massin et al. [2] N – – 
Kluba  et al. [21] M Unclear Unclear 
Sabatini et al. [11] M Unclear Unclear 
Notarnicola et al. [17] Y, stratiﬁed random Unclear Y, double b
Levy  et al. [16] Y,centralized random Y Y, single b
Skovgaard et al. [22] Y, random sequence Y Y, double b
Wang et al. [14] M Unclear Y, single b
Wang et al. [12] M Unclear Y, single b
Everts et al. [13] N – – 
Everts et al. [23] N – – 
Spinarelli et al. [18] N – – 
Molloy et al. [19] Y, block balance random Y Y, double b
Aguilera et al. [20] Y, block balance random Y N 
: the method was  not used in the study; M:  the method was  mentioned, but there wa
nclear: no relevant information was found in the study.11.9 ± 0.9/12.0 ± 0.7 10 mL  FS vs blank control
0/74.9 ± 7.0 13.4 ± 2.2/13.4 ± 1.2 6 mL  FS vs blank control
ntrolled trials; pCS: prospective comparative study.
reduction compared to the control group [MD  = 1.14; 95% CI
(0.61–1.67); P < 0.01; I2 = 86%]. A subgroup analysis of two studies
[11,17] showed that low-dose ﬁbrin sealant led to an Hb reduc-
tion by a mean of 0.68 mg/dL [95% CI (0.01–1.67); P = 0.05; I2 = 46%].
A subgroup analysis of four studies revealed that high-dose ﬁbrin
sealant also led to an Hb reduction by a mean of 1.34 mg/dL [95%
Comparable
baseline
> 80% follow-up Free of selective
reporting
Level
Y Y Y C
Y Y Y C
Y Y Y C
lind Y Y Y A
lind Y Y Y A
lind Y Y Y A
lind Y Y Y B
lind Y Y Y B
Y Y Unclear C
Y Y Unclear C
Y Y Unclear C
lind Y Y Y A
Y Y Y A
s not detailed description; Y: the method was reported with detailed description.
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I (0.58–2.10); P = 0.0006], as shown in Fig. 6 [14,16–18]. Due to
eterogeneity (I2 = 91%), the random-effects model was used.
.3.5. Hospital stay
Using the random-effects model (I2 = 93%), we discovered that
brin sealant reduced hospital stay by a mean of 2.22 days com-
ared to the control group [95% CI (0.56–3.88); P = 0.009]. A
ubgroup analysis of two studies [17,21] showed that a low-dose
f ﬁbrin sealant reduced hospital stay by a mean of 2.77 days com-
ared to the control group [95% CI (0.39–5.14); P = 0.02; I2 = 54%]. subgroup analysis of three studies [13,17,20] showed that a
igh-dose of ﬁbrin sealant reduced hospital stay by a mean of
.97 days compared to the control group [95% CI (–0.41–4.36);
 = 0.11; I2 = 93%; Fig. 7].
Fig. 3. Subgroup meta-analysis of draind loss between the two groups.
3.3.6. The incidence of complications
A pooled analysis using the ﬁxed-effects model (I2 = 28%)
revealed a signiﬁcant reduction in the incidence of complica-
tions in the treatment group [OR = 0.56; 95% CI (0.38–0.83);
P = 0.003].
Three studies [11,12,16] reported fever and there was no signif-
icant difference between the groups [OR = 1.06; 95% CI (0.60–1.90);
P = 0.87]. Three studies [11,14,23] reported hematomas and there
was a signiﬁcant difference [OR = 0.26; 95% CI (0.07–1.01);
P = 0.05]. Three studies [16,17,19] reported thrombosis, and there
was no signiﬁcant difference [OR = 2.26; 95% CI (0.50–10.35);
P = 0.29]. Two  studies [12,23] reported arthropathy and there
was a signiﬁcant difference [OR = 0.15; 95% CI (0.04–0.58);
P = 0.65]. Four studies [12,13,16,19] reported wound infection,
 output between the two groups.
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nce of
a
(
s
(Fig. 4. Subgroup meta-analysis of the incidend there was no signiﬁcant difference [OR = 0.47; 95% CI
0.16–1.39); P = 0.17]. Only one study [13] reported that ﬁbrin
ealant could signiﬁcantly reduce the incidence of wound leakage
Fig. 8).
Fig. 5. Subgroup meta-analysis of blood tran blood transfusion between the two groups.3.3.7. Sensitivity analysis
Sensitivity analysis was performed by omitting the non-RCT
[2,13,18,23] and the poor quality studies [11,21]. The results
showed similar trend for a decrease in Hb reduction, total blood
sfusion unit between the two  groups.
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sFig. 6. Subgroup meta-analysis of hem
oss, the transfusion rate, transfusion units, and hospital stay, while
hey showed different trend for a reduction in the incidence of
omplications.
.3.8. Publication bias
Funnel plots were adopted to evaluate the publication bias. The
hapes of funnel plots for Hb reduction, transfusion rate (Fig. 9),
nd the incidence of complications did not reveal asymmetry, indi-
ating no evidence of publication bias.
. DiscussionThe present meta-analysis showed that the use of ﬁbrin sealant
ight reduce the transfusion rate and transfusion units following
KR, but that the effect of reducing the total blood loss was not
igniﬁcant.
Fig. 7. Subgroup meta-analysis of hospin reduction between the two  groups.
4.1. Blood transfusion
The group treated with ﬁbrin sealant had a lower transfusion
rate and transfusion units. After adjusting speciﬁc patient charac-
teristics (such as age, sex, cardiovascular history, ASA score and
anaemia severity), most studies followed protocol recommended
by 1988 National Institutes of Health consensus conference indicat-
ing 8 g/dL as the lowest acceptable Hb concentration. It was noted
that different protocols for blood transfusion were followed in two
studies [7,10], and the transfusion criteria was Hb value less than
8.8 g/dL or 10 g/dL. So, they are more easily to order transfusion than
others, and this would be a potential source of heterogeneity. Mean-
while, one study mentioned that the control group had a lower
preoperative Hb level than treatment group [2], and therefore per-
haps inducing a higher transfusion rate, which might inﬂuence the
result.
ital stay between the two groups.
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Fig. 8. Subgroup meta-analysis of the incidence of complications between the two  groups.
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.2. Blood loss
Drain-out volume and/or total blood loss was adopted as out-
ome measures. The results demonstrated that low- and high-dose
brin sealant signiﬁcantly decreased the drain-out volume and
brin sealant also decreased total blood loss, while it failed to reach
tatistical signiﬁcance. Excepted for one study using Mercuriali and
nghilerri formula [19], all the other studies adopted the method of
ross [2,16,20] to calculate the total blood loss. As known, after
djusting the patients’ weight and height, gross formula used the
ean Hb reduction of preoperative and the lowest postoperative
alues, while Mercuriali and Inghilerri formula used the mean Hb
eduction of preoperative and the postoperative 6 days values [24],
hich will get a lower total blood loss. As the calculated method
as same between the treatment and control group in each study,
o this may  be a potential source of heterogeneity, but would not
ffect the pooled result.
The results showed that after using ﬁbrin sealant, the Hb reduc-
ion and drain-out volume were both decreased. While, in the
ncluded studies, one study did not apply wound drains [13], and
he drain-out volume may  be affected by patient condition, the
urgeons’ experience, drain removal time and hidden blood loss
additional blood stasis in the soft tissue of the knee) [5,14,25–27].
Besides, four studies [2,17,22,23] reported that the range of ﬂex-
on signiﬁcantly improved after treatment with ﬁbrin sealant. This
ubsequently contributed to a signiﬁcantly shorter hospital stay,
ndicating that ﬁbrin sealant can speed up knee function recovery.
nd one study [21], which included patients with bilateral knee
steoarthritis, reported no signiﬁcant difference between the ﬁbrin
ealant group and the control group. The data could not be analyzed,
ecause different detection times were used.
The meta-analysis indicated that ﬁbrin sealant reduced the inci-
ence of overall complications and a further subgroup analysis
howed that the risk of hematoma, arthropathy and wound leakage
as signiﬁcantly reduced compared to the control group. Due to
nsufﬁcient data, it was not possible to assess ﬁnancial differences
n our analysis, as only one study [2] performed a cost analysis. The
tudy suggested that the cost of the additional 31 units of ﬁbrin
ealant was 9743 D , whereas the cost savings achieved by using
1 fewer blood transfusion units was only 3484 D , indicating that
brin sealant treatment was still the more expensive option.
Subgroup analyses revealed similar results for low dosages and
igh dosages of ﬁbrin sealant. The results from the low dosage sub-
roup should be considered carefully as there were only a small
umber of trials and few patients. In addition, only four RCTs
2,9,11,17] were included in the low dosage subgroup and one of
hese included a trial [9] that used only 2 mL  of ﬁbrin sealant; this Surgery & Research 101 (2015) 331–339
heterogeneity of dosage may  have affected the results. Similarly,
six RCTs were included in the high dosage subgroup, and one of
these trials [16] used a ﬁbrin sealant mixture that ranged from 5 mL
to 10 mL  and did not include a detailed description; this may  also
have a negative effect on the analysis. Finally, the subgroup anal-
yses demonstrated that a high-dose of ﬁbrin sealant resulted in
effective management of postoperative bleeding, functional recov-
ery and reduced complications. There was  not enough evidence to
draw a conclusion on the effectiveness of low-doses of ﬁbrin sealant
in knee surgery.
Although standard procedures for retrieval, assessment of
relevance and statistical processing were performed in this meta-
analysis, some potential limitations also should be taken into
account:
• methodological limitations of RCTs, including and absence of
blind allocation in the randomization process;
• clinical and statistical heterogeneity, including differences in
patient population, the description and experience of different
surgeons, outcome evaluation method and follow-up time [28];
• hospital stay in this review may  not shed much light on the rel-
ative role of ﬁbrin sealant, which was used mainly as a adjuvant
bleeding prevention medicine;
• due to unpublished or unidentiﬁed clinical trials, publication bias
might jeopardize the validity of this meta-analysis.
Some other possible forms of bias and potential source of het-
erogeneity should also be mentioned. Massin et al. [2] did not
use a tourniquet intraoperative, which might increase the risk of
bleeding. Levy et al. [16] did not describe detailed procedures or
information about surgeons from different centres. Wang et al. [14]
did not offer any information on methodology, patients’ charac-
ter or surgeons’ experience. Skovgaard [21] included patients with
serious health conditions.
In conclusion, patients undergoing knee surgery would beneﬁt
from high-dose ﬁbrin sealant with reduced transfusion rate and
unit, hospital stay and complications, while they might beneﬁt little
from it in total blood loss. However, the effects of a low-dose of
ﬁbrin in knee surgery remain inconclusive.
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